HC Wainwright & Co. Maintains Buy on Aktis Oncology, Raises Price Target to $33

HC Wainwright & Co. analyst Robert Burns maintains Aktis Oncology (NASDAQ:AKTS) with a Buy and raises the price target from $30 to $33.